FDA Clears New Methylphenidate Formulation for ADHD

By |2021-11-11T17:07:13-08:00June 20th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

The US Food and Drug Administration (FDA) has approved a new formulation of methylphenidate for children with attention-deficit/hyperactivity disorder (ADHD). Cotempla XR-ODT (Neos Therapeutics Inc) is the first and only methylphenidate extended-release orally disintegrating tablet for the treatment of ADHD in patients aged 6 to 17 years, the company said [...]

Teen Depression Linked to Persistent Sleep-Disordered Breathing

By |2021-11-11T17:07:22-08:00June 19th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

By Megan Brooks BOSTON — Sleep-disordered breathing (SDB) may play a role in persistent depressive symptoms and poor response to standard pharmacologic treatments in adolescents, new research suggests. Screening adolescents with treatment-resistant depression (TRD) for SBD "may be clinically valuable, since SDB is readily treatable," said Teena Chase, MD, PhD, Department [...]

Diuretic Continues to Show Promise in Autism

By |2021-11-11T17:13:58-08:00March 23rd, 2017|Brief Bulletins from the Field, We Know Psychiatry|

Treatment with the diuretic bumetanide (Bumex, Validus) improved core symptoms of autism spectrum disorder (ASD), including social deficits and stereotyped behaviors, results from a multicenter phase 2b study show. Bumetanide was effective in improving ASD-related symptoms across the pediatric age range, as assessed by the Childhood Autism Rating Scale (CARS), [...]

Title

Go to Top